A5012281844- Dermatology and Skin Diseases
- Immunotherapy and Immune Responses
- Asthma and respiratory diseases
- Psoriasis: Treatment and Pathogenesis
- Urticaria and Related Conditions
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Allergic Rhinitis and Sensitization
- Pancreatic function and diabetes
- Cutaneous lymphoproliferative disorders research
- Diabetes and associated disorders
- T-cell and B-cell Immunology
- Hair Growth and Disorders
- Immune cells in cancer
- Lymphoma Diagnosis and Treatment
- melanin and skin pigmentation
- Pluripotent Stem Cells Research
- Pharmaceutical studies and practices
- Wound Healing and Treatments
- IL-33, ST2, and ILC Pathways
- Xenotransplantation and immune response
- Cancer Immunotherapy and Biomarkers
- Skin Protection and Aging
- Heterotopic Ossification and Related Conditions
- Medication Adherence and Compliance
Icahn School of Medicine at Mount Sinai
2018-2024
Columbia University
2019-2021
Massachusetts General Hospital
2015-2018
Harvard University
2015-2018
United States Department of Veterans Affairs
1986
BackgroundInterleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function.ObjectiveEvaluate interleukin blockade in adults with moderate-to-severe atopic dermatitis (AD).MethodsWe performed a randomized, double-blind, placebo-controlled trial intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, follow-up assessments until 20 weeks. The change SCOring AD (SCORAD) score from baseline at 12 served as the primary end point.ResultsAt mean declines SCORAD entire study...
Major barriers to cancer therapy include the lack of selective inhibitors regulatory T cells (Tregs) and broadly applicable ways directly target tumors through frequently expressed surface oncogenes. Tumor necrosis factor receptor 2 (TNFR2) is an attractive protein because its restricted abundance highly immunosuppressive Tregs oncogenic presence on human tumors. We characterized effect TNFR2 inhibition using antagonistic antibodies. In culture-based assays, we found that two antagonists...
Mycobacterium are among the oldest co-evolutionary partners of humans. The attenuated bovis Bacillus Calmette Guérin (BCG) strain has been administered globally for 100 years as a vaccine against tuberculosis. BCG also shows promise treatment numerous inflammatory and autoimmune diseases. Here, we report on randomized 8-year long prospective examination type 1 diabetic subjects with long-term disease who received two doses vaccine. After year 3, lowered hemoglobin A1c to near normal levels...
Sézary syndrome (SS) is a rare form of cutaneous T-cell lymphoma often refractory to treatment. SS defined as adenopathy, erythroderma with high numbers atypical T cells. This offers an opportunity for new interventions and perhaps antibody-based therapeutic by virtue its expression the TNFR2 oncogene on tumor cells T-regulatory (Tregs). Potent human-directed antagonistic antibodies have been created that preferentially target tumor-infiltrating TNFR2+ Tregs. Here we test potential...
In the SARS-CoV-2/COVID-19 pandemic, we need to understand impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including type 2/Th2 polarized skin disease, atopic dermatitis (AD).Because it is believed that 1/Th1 immunity controls viral infections and there a Th1/Th2 counter-regulation, hypothesized Th2 targeting IL-4Rα-antagonist, dupilumab, moderate-to-severe AD would rebalance axis, potentially leading attenuated symptoms.A total...
Limitations in cell proliferation are important for normal function of differentiated tissues and essential the safety replacement products made from pluripotent stem cells, which have unlimited proliferative potential. To evaluate whether these limitations can be established pharmacologically, we exposed pancreatic progenitors differentiating human cells to small molecules that interfere with cycle progression either by inducing G1 arrest or impairing S phase entry completion determined...
AbstractThe aim of the study was to determine whether self-management skills, when taught asthmatic children and their parents, would improve medication compliance. The latter assessed by a variety procedures including serum theophylline levels, pill counts self-monitoring measures. Results indicated group receiving training showed no greater gains in compliance, self-concept, or health locus control than did self-monitoring-only group. However, former became more responsible for initiating...
Several autoimmune diseases are marked by a deficiency of soluble tumor necrosis factor (TNF). The TNF is caused in at least one disease, multiple sclerosis, an overabundance receptor 1 (TNFR1). Excess TNFR1 binds and inactivates this leaves less bioavailable. This study sought to determine if expression fresh or IL2-stimulated receptors on Tregs cells, important immunoregulatory cell involved autoimmunity, altered type I diabetes. Standard fluorescence analysis was used examine the levels...
Background: In the SARS-CoV-2/COVID-19 pandemic, we need to understand impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including Type 2/Th2 polarized skin disease, atopic dermatitis/AD. Since it is believed that 1/Th1immunity controls viral infections, and there a Th1/Th2 counter-regulation, hypothesized Th2 targeting IL-4Rα-antagonist, dupilumab, moderate-to-severe AD rebalances axis, potentially leading attenuated symptoms....
Abstract Background: Tumor necrosis factor receptor 2 (TNFR2, or TNFRSF1B) is a lymphoid marker of the most potent regulatory T cell (Treg) subtype and commonly expressed oncogene in human tumors. TNFR2 Tregs are also enriched tumor microenvironment. Recently, antagonistic antibodies have been made that inhibit NFkB-driven growth through receptor. These antagonists shown both Treg inhibition with specificity for microenvironment (Science Signaling 2017). Cutaneous lymphoma (CTCL) currently...
Abstract A major barrier to cancer immunotherapy is lack of selective inhibitors the regulatory T cells (Tregs) microenvironment and methods directly kill tumors through novel surface oncogenes. Tumor necrosis factor receptor 2 (TNFR2) a target protein with restricted expression on most potent Tregs tumor infiltrate human as newly discovered oncogene. We characterized effect TNFR2 antibody antagonists via in samples from ovarian ascites compared healthy controls. potently inhibited Treg...
Abstract Background: Although antibody targeting of the HER2 oncogene represents an outstanding clinical treatment and a success story showing direct cancer killing with antibodies, many oncogenes are intracellular not expressed broadly, whether on single or multiple tumor types. The recently discovered TNFR2 is broadly human tumors. Colon cells, myeloma renal cell carcinoma Hodgkin’s lymphoma ovarian epithelial cells cutaneous non-Hodgkin’s can aberrantly express receptor as for growth. For...
Abstract Background: A recognized and potent subtype of regulatory T cells (Tregs) expresses tumor necrosis factor receptor 2 (TNFR2), a member the (TNF) superfamily. TNFR2 expressing Tregs are overabundant in human murine tumors most suppressors host immune responses. In addition, recent data diverse show that TNFR2-expressing dominant microenvironment, expressed far excess OX40 GITR. Unlike many markers, has limited expression system almost no on parenchymal cells. This makes an attractive...
106 Background: A major barrier to cancer immunotherapy is lack of selective inhibitors the regulatory T cells (Tregs) microenvironment and methods directly kill tumors through novel surface oncogenes. Tumor necrosis factor receptor 2 (TNFR2) a target protein with restricted expression on most potent Tregs tumor infiltrate newly identified as broadly expressed oncogene human tumors. Methods: We characterized effect TNFR2 antibody antagonists via in samples from ovarian ascites compared...
Abstract Background: Tumor necrosis factor receptor 2 (TNFR2, or TNFRSF1B) is a lymphoid marker of the most potent regulatory T cell (Treg) subtype and commonly expressed oncogene in human tumors. TNFR2 Tregs are also enriched tumor microenvironment. antagonistic antibodies have been recently developed to inhibit NFkB-driven growth through receptor, showing both Treg inhibition with specificity for microenvironment (Sci Signaling 2017). candidate cutaneous lymphoma (CTCL), recurrent point...
Type I diabetes (T1D) is caused by immune-mediated destruction of pancreatic beta cells. This process triggered, in part, specific (aa 9-23) epitopes the insulin Β chain. Previously, fish insulins were used clinically patients allergic to bovine or porcine insulin. Fish and human differ two amino acids critical immunogenic region B We hypothesized that β cells synthesizing would be less a mouse model T1D. Transgenic NOD mice which Greater Amberjack (Seriola dumerili) was substituted for 2...